By now, most of us have probably heard of Alzheimer’s disease (AD).
The disease, which is found in the brains of people 65 and older, is the leading cause of death in the US, and is responsible for about one in every seven deaths.
But while Alzheimer’s is generally considered a progressive disease, some people may be at a higher risk for the disease.
A study published last month by researchers at the National Institute of Neurological Disorders and Stroke (NINDS) showed that a group of people with AD had significantly lower cognitive performance when compared to healthy people.
The study found that a number of brain regions are activated in people with the disease, and the researchers also found that those who have AD may have a higher number of different types of cells in their brains.
Researchers believe that the brain’s protective cells protect the brain from damaging damage by keeping things running smoothly, and by helping to process information in a way that allows it to operate efficiently.
So, why are people with mild to moderate AD more likely to have cognitive problems than people who are not?
Researchers have found that the type of brain cells that are activated may have an effect on brain function.
People with less than 1 percent of cells that make up nerve cells in the brain are thought to have fewer brain cells than people with higher levels of those cells, which may result in less functioning of these nerve cells, said lead researcher and neuroscientist, Dr. Susan Waddington.
Waddey said that cells that contain nerve cells also produce neurotransmitters that affect how our brains function.
In a study published in the Journal of Neuroscience, Drs.
Jennifer Henschke and Stephen A. Stolarz found that when mice were exposed to a specific chemical, the brain cells in these cells became more sensitive to the chemicals, which can be a sign of a higher level of inflammation in the body.
This chemical, called a neurotoxin, also affects the immune system and can lead to a range of problems, including asthma and allergies.
A second study, published in Neuroscience in March, found that AD patients who had high levels of a neurotoxic compound called N-acetylcysteine (NAC) had significantly less cells in certain brain regions that are involved in processing information.
The researchers believe that NAC may play a role in the way people with brain cancer react to brain stimulation.
Dr. David Katz, a professor of neurology at the University of Pennsylvania School of Medicine and one of the authors of the study, said that people with cognitive impairment have more cells in specific brain areas than people without AD.
“It is very common in people who have dementia for people to have increased numbers of cells throughout the brain,” Katz said.
Katz added that the fact that AD sufferers have increased cell numbers also indicates that the disease is not the only factor that can contribute to cognitive problems.
“It is possible that other environmental factors may be associated with brain dysfunction,” Katz told Healthline.
“If the disease isn’t being addressed, it’s possible that the amount of cells involved will increase.”
Hensche and Stolarzer are currently looking at other studies to better understand how these cells can affect the brain.
They are also working to find out whether other types of cell types, such as white blood cells, could also play a part in brain function, Katz said, adding that they also are looking at whether a brain scan can help with treatment of AD.